Mutations in several oncogenes are well-characterized driver events in various cancers, e.g., mutations in KRAS G12 residue in pancreatic and lung cancer,3 BRAF V600 in melanoma,4 and the EGFR L858 in lung cancer.5 Here, KRAS is linked to lung cancer.